Sanofi has announced that #Venglustat met the primary endpoint and 3 out of 4 secondary endpoints in the phase 3 study evaluating the once-daily oral therapy for patients with type 3 #GaucherDisease (GD).
Read more: https://bit.ly/3NVWSqC
#RareDisease #GD #MedSky
2
0
0
0